The Experts below are selected from a list of 3693 Experts worldwide ranked by ideXlab platform
Anthony W. Stanson - One of the best experts on this subject based on the ideXlab platform.
-
Renal Artery Stent placement for restoration of Renal function in hemodialysis recipients with Renal Artery stenosis.
Journal of vascular and interventional radiology : JVIR, 2008Co-Authors: Mallik R. Thatipelli, C. Michael Johnson, James C. Andrews, Haraldur Bjarnason, Sanjay Misra, Anthony W. Stanson, Michael A. MckusickAbstract:Purpose Renal Artery Stent placement to treat Renal Artery stenosis (RAS) in patients undergoing hemodialysis is not performed commonly. We present our outcomes of discontinuation of hemodialysis after treating patients with RAS by Stent placement on acute (≤30 days of hemodialysis) and chronic hemodialysis (>30 days). Materials and Methods A retrospective study was conducted in 16 patients (nine men) with an average age of 74.6 years ± 10.6 (range, 49–86 y) who underwent treatment of 22 RAS for acute Renal failure ( n = 8) or uncontrolled hypertension with chronic hemodialysis ( n = 8). The average follow-up was 448 days ± 450 (median, 363.5 d; range, 6–1,583 d). The primary outcome consisted of discontinuation of hemodialysis, death, and transplantation. Secondary endpoints included restenosis, changes in blood pressure (and use of medications), and estimated glomerular filtration rate (eGFR). Results After the Stent procedure, eight patients were able to discontinue hemodialysis and remained free from dialysis over a mean period of 564 days ± 533. The predictors of discontinuation of hemodialysis were 24-hour proteinuria, eGFR before Renal Artery Stent placement, and size of the kidney on ultrasound studies ( P Conclusions Renal Artery Stent placement for the treatment of RAS in patients receiving hemodialysis can result in discontinuation of hemodialysis in patients with low proteinuria level and adequate kidney size and eGFR.
-
Renal Artery Stent placement: complications at a single tertiary care center.
Journal of Vascular and Interventional Radiology, 2003Co-Authors: Vladimir Ivanovic, Michael A. Mckusick, C. Michael Johnson, Enrique A. Sabater, James C. Andrews, Jerome F. Breen, Haraldur Bjarnason, Sanjay Misra, Anthony W. StansonAbstract:PURPOSE To describe complications after Renal Artery Stent placement in patients with atherosclerotic Renal Artery stenosis (RAS) at a single tertiary care center and analyze the risk factors for these complications. MATERIALS AND METHODS Medical records and angiograms of 171 patients who underwent a total of 179 consecutive percutaneous transluminal Renal Artery Stent placement (PTRS) procedures for atherosclerotic RAS were retrospectively reviewed. Data on patient comorbidities, procedure indication, lesion location, serum creatinine level, and procedure-related complications were analyzed. The Wilcoxon rank-sum test was used to assess the association of continuous risk factors with complications, and the χ 2 test was used to assess the association of categoric risk factors with outcomes. RESULTS The technical success rate for PTRS was 98%. Major complications included Renal infarction in five patients (2.8%), permanently increased serum creatinine level in 10 patients (5.6%) that required hemodialysis in five (2.8%), blood transfusion in four patients (2.2%), surgical intervention for procedure-related complications in two patients (1.1%), and deep vein thrombosis in one patient (0.6%). Overall, major complications occurred in 15 procedures (8.4%). Death within 30 days after PTRS occurred in two patients (1.1%), but neither death was definitively caused by the procedure. No risk factors were found to be significantly ( P P = .01) and have higher creatinine levels ( P = .06). CONCLUSIONS Renal Artery Stent placement allows treatment of advanced atheromatous RAS in patients with significant medical and surgical comorbidities. Complications are frequent but few have long-term significance.
-
Renal Artery Stent placement: complications at a single tertiary care center.
Journal of vascular and interventional radiology : JVIR, 2003Co-Authors: Vladimir Ivanovic, Michael A. Mckusick, C. Michael Johnson, Enrique A. Sabater, James C. Andrews, Jerome F. Breen, Haraldur Bjarnason, Sanjay Misra, Anthony W. StansonAbstract:To describe complications after Renal Artery Stent placement in patients with atherosclerotic Renal Artery stenosis (RAS) at a single tertiary care center and analyze the risk factors for these complications. Medical records and angiograms of 171 patients who underwent a total of 179 consecutive percutaneous transluminal Renal Artery Stent placement (PTRS) procedures for atherosclerotic RAS were retrospectively reviewed. Data on patient comorbidities, procedure indication, lesion location, serum creatinine level, and procedure-related complications were analyzed. The Wilcoxon rank-sum test was used to assess the association of continuous risk factors with complications, and the chi(2) test was used to assess the association of categoric risk factors with outcomes. The technical success rate for PTRS was 98%. Major complications included Renal infarction in five patients (2.8%), permanently increased serum creatinine level in 10 patients (5.6%) that required hemodialysis in five (2.8%), blood transfusion in four patients (2.2%), surgical intervention for procedure-related complications in two patients (1.1%), and deep vein thrombosis in one patient (0.6%). Overall, major complications occurred in 15 procedures (8.4%). Death within 30 days after PTRS occurred in two patients (1.1%), but neither death was definitively caused by the procedure. No risk factors were found to be significantly (P <.05) associated with major complications. Patients with Renal Artery site or Renal function complications tended to be older (P =.01) and have higher creatinine levels (P =.06). Renal Artery Stent placement allows treatment of advanced atheromatous RAS in patients with significant medical and surgical comorbidities. Complications are frequent but few have long-term significance.
Sanjay Misra - One of the best experts on this subject based on the ideXlab platform.
-
treatment of in Stent restenosis in patients with Renal Artery stenosis
Journal of Vascular and Interventional Radiology, 2016Co-Authors: Edwin A Takahashi, Michael A. Mckusick, Haraldur Bjarnason, William S Harmsen, Ameet Piryani, Sanjay MisraAbstract:Abstract Purpose To determine clinical outcomes of patients treated for Renal Artery in-Stent restenosis (ISR) with atherosclerotic Renal Artery stenosis. Materials and Methods A retrospective review was performed of the clinical data of all patients who underwent Renal Artery Stent placement for atherosclerotic Renal Artery stenosis from 1996 to 2009. Medical records of patients were reviewed for relevant clinical history, including blood pressure, antihypertensive medications, and Renal function data before and after an intervention. In 1,052 patients, 1,090 Renal Artery Stent placements were performed. Of these, 101 Stents in 79 patients developed ISR, which was treated with either percutaneous transluminal angioplasty (PTA) or repeat Stent placement. Procedural details, including modality of intervention, Stent diameter, and time to restenosis, were recorded. Hypertensive agent and use of statins were recorded. Univariate analysis was performed to identify risk factors associated with restenosis after treatment of ISR. Results Patients treated with repeat Stent placement were 6.89 times more likely to lose patency after treatment than patients treated with PTA ( P Conclusions Treatment of Renal Artery ISR with PTA among patients with atherosclerotic Renal Artery stenosis has a lower rate of subsequent ISR compared with repeat Stent placement.
-
mortality and Renal replacement therapy after Renal Artery Stent placement for atherosclerotic renovascular disease
Journal of Vascular and Interventional Radiology, 2016Co-Authors: Sanjay Misra, Ankaj Khosla, Jake Allred, William S Harmsen, Stephen C Textor, Michael A. MckusickAbstract:Abstract Purpose To identify risk factors for progression to Renal replacement therapy (RRT) and all-cause mortality in patients who underwent Renal Artery (RA) Stent placement for atherosclerotic Renal Artery stenosis (RAS). Materials and Methods A retrospective study from June 1996 to June 2009 identified 1,052 patients who underwent RA Stent placement. Glomerular filtration rate at time of RA Stent placement was estimated from serum creatinine level and divided into chronic kidney disease (CKD) stages 1–5. Univariate and multivariable Cox proportional hazards models were used to determine which factors were associated with each endpoint. Results Times to progression to all-cause mortality and RRT were similar for CKD stages 1/2/3A and served as the reference group. In multivariable analysis, high-grade proteinuria ( P P P P = .02]) remained independently associated with increased risk of progression to RRT. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) use was associated with decreased risk of progression to RRT ( P = .03). Higher CKD stage (5 vs 1/2/3A [ P P = .004]), carotid Artery disease ( P P = .002), and high-grade proteinuria ( P P Conclusions Patients with atherosclerotic RAS who undergo RA Stent placement and have high-grade proteinuria and CKD stage 3B/4/5 have increased risk of progression to RRT. Patients with high-grade proteinuria, CKD stage 3B/4/5, carotid Artery disease, or diabetes have increased risk for all-cause mortality after Renal Artery Stent placement. Patients receiving ACEI/ARBs have a decreased risk of progression to RRT, and patients receiving statins have a decreased risk of all-cause mortality.
-
An analysis of the factors influencing radiation dose and fluoroscopic time during Renal Artery Stent placement.
Vascular and endovascular surgery, 2013Co-Authors: J. Mcbride, B. Schueler, Gustavo S. Oderich, Sanjay MisraAbstract:Purpose:To determine the factors that affect mean absorbed dose and fluoroscopic times during Renal Artery Stent placement. Materials andMethods:After institutional review board approval, the HI-IQ database was queried for patients undergoing Renal Artery Stent placement only from January 2007 to June 2010. Procedures that were performed as part of other procedures such as iliac Artery Stents were excluded. The HI-IQ data included fluoroscopy time (f) and radiation dose (mGy). Demographic, medical history, procedural details, and advanced preprocedural Renal Artery Stent imaging were obtained. Variables (number of Stents, average body mass index , number of Stents placed per year and number of years’ service of an interventional physician, pre-procedural imaging, and use of embolic protection device) were analyzed using a t test after log transformation and testing for variance with an F test.Results:A total of 134 patients (75 males, 70.6 ± 10.5 years old) underwent the placement of 177 Renal Artery sten...
-
Embolic protection device use in Renal Artery Stent placement.
Journal of vascular and interventional radiology : JVIR, 2009Co-Authors: Mallik R. Thatipelli, Sanjay Misra, Srinivas R. Sanikommu, Robert M. Schainfeld, Sandeep K. Sharma, Peter A. SoukasAbstract:Purpose The purpose of the present study was to report safety, efficacy, and Renal function outcomes with use of the GuardWire embolic protection device (EPD) in Renal Artery Stent placement for patients with Renal Artery stenosis (RAS) and chronic Renal insufficiency (CRI). Materials and Methods This was a retrospective study of all patients with RAS and CRI treated concomitantly with a GuardWire EPD and Renal Artery Stents from December 2002 through June 2006. Renal function was determined by calculating the estimated glomerular filtration rate (eGFR) according to the Modification of Diet in Renal Disease formula, and subjects were divided into Kidney Disease Outcomes and Quality Initiative (K-DOQI) classes based on baseline eGFR. After revascularization, an improvement from baseline of at least one K-DOQI class was defined as improvement, unchanged K-DOQI class as stabilization, and worsening of at least one K-DOQI class as deterioration. Results There were 63 patients (54% men) with a mean age of 75.2 years ± 7.7. The mean baseline serum creatinine level and eGFR were 1.87 mg/dL ± 0.6 (range, 1–3.8 mg/dL) and 36.63 mL/min per 1.73 m 2 ± 11.42 (range, 13.85–59.99 mL/min per 1.73 m 2 ), respectively, and at the last clinical follow-up, the respective measurements were 1.96 mg/dL ± 0.72 and 38.75 mL/min per 1.73 m 2 ± 13.25 ( P = not significant). Over a mean follow-up period of 16 months ± 12, 14 patients (25%) showed improvement, 33 (58%) had stable Renal function, and 10 (18%) showed deterioration. There was one GuardWire-related dissection, which was successfully treated with a Stent. Conclusions The GuardWire EPD, used during Renal Artery Stent placement, is safe and was associated with stabilization or improvement in kidney function in 83% of patients with RAS and CRI.
-
Renal Artery Stent placement for restoration of Renal function in hemodialysis recipients with Renal Artery stenosis.
Journal of vascular and interventional radiology : JVIR, 2008Co-Authors: Mallik R. Thatipelli, C. Michael Johnson, James C. Andrews, Haraldur Bjarnason, Sanjay Misra, Anthony W. Stanson, Michael A. MckusickAbstract:Purpose Renal Artery Stent placement to treat Renal Artery stenosis (RAS) in patients undergoing hemodialysis is not performed commonly. We present our outcomes of discontinuation of hemodialysis after treating patients with RAS by Stent placement on acute (≤30 days of hemodialysis) and chronic hemodialysis (>30 days). Materials and Methods A retrospective study was conducted in 16 patients (nine men) with an average age of 74.6 years ± 10.6 (range, 49–86 y) who underwent treatment of 22 RAS for acute Renal failure ( n = 8) or uncontrolled hypertension with chronic hemodialysis ( n = 8). The average follow-up was 448 days ± 450 (median, 363.5 d; range, 6–1,583 d). The primary outcome consisted of discontinuation of hemodialysis, death, and transplantation. Secondary endpoints included restenosis, changes in blood pressure (and use of medications), and estimated glomerular filtration rate (eGFR). Results After the Stent procedure, eight patients were able to discontinue hemodialysis and remained free from dialysis over a mean period of 564 days ± 533. The predictors of discontinuation of hemodialysis were 24-hour proteinuria, eGFR before Renal Artery Stent placement, and size of the kidney on ultrasound studies ( P Conclusions Renal Artery Stent placement for the treatment of RAS in patients receiving hemodialysis can result in discontinuation of hemodialysis in patients with low proteinuria level and adequate kidney size and eGFR.
Michael A. Mckusick - One of the best experts on this subject based on the ideXlab platform.
-
treatment of in Stent restenosis in patients with Renal Artery stenosis
Journal of Vascular and Interventional Radiology, 2016Co-Authors: Edwin A Takahashi, Michael A. Mckusick, Haraldur Bjarnason, William S Harmsen, Ameet Piryani, Sanjay MisraAbstract:Abstract Purpose To determine clinical outcomes of patients treated for Renal Artery in-Stent restenosis (ISR) with atherosclerotic Renal Artery stenosis. Materials and Methods A retrospective review was performed of the clinical data of all patients who underwent Renal Artery Stent placement for atherosclerotic Renal Artery stenosis from 1996 to 2009. Medical records of patients were reviewed for relevant clinical history, including blood pressure, antihypertensive medications, and Renal function data before and after an intervention. In 1,052 patients, 1,090 Renal Artery Stent placements were performed. Of these, 101 Stents in 79 patients developed ISR, which was treated with either percutaneous transluminal angioplasty (PTA) or repeat Stent placement. Procedural details, including modality of intervention, Stent diameter, and time to restenosis, were recorded. Hypertensive agent and use of statins were recorded. Univariate analysis was performed to identify risk factors associated with restenosis after treatment of ISR. Results Patients treated with repeat Stent placement were 6.89 times more likely to lose patency after treatment than patients treated with PTA ( P Conclusions Treatment of Renal Artery ISR with PTA among patients with atherosclerotic Renal Artery stenosis has a lower rate of subsequent ISR compared with repeat Stent placement.
-
mortality and Renal replacement therapy after Renal Artery Stent placement for atherosclerotic renovascular disease
Journal of Vascular and Interventional Radiology, 2016Co-Authors: Sanjay Misra, Ankaj Khosla, Jake Allred, William S Harmsen, Stephen C Textor, Michael A. MckusickAbstract:Abstract Purpose To identify risk factors for progression to Renal replacement therapy (RRT) and all-cause mortality in patients who underwent Renal Artery (RA) Stent placement for atherosclerotic Renal Artery stenosis (RAS). Materials and Methods A retrospective study from June 1996 to June 2009 identified 1,052 patients who underwent RA Stent placement. Glomerular filtration rate at time of RA Stent placement was estimated from serum creatinine level and divided into chronic kidney disease (CKD) stages 1–5. Univariate and multivariable Cox proportional hazards models were used to determine which factors were associated with each endpoint. Results Times to progression to all-cause mortality and RRT were similar for CKD stages 1/2/3A and served as the reference group. In multivariable analysis, high-grade proteinuria ( P P P P = .02]) remained independently associated with increased risk of progression to RRT. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) use was associated with decreased risk of progression to RRT ( P = .03). Higher CKD stage (5 vs 1/2/3A [ P P = .004]), carotid Artery disease ( P P = .002), and high-grade proteinuria ( P P Conclusions Patients with atherosclerotic RAS who undergo RA Stent placement and have high-grade proteinuria and CKD stage 3B/4/5 have increased risk of progression to RRT. Patients with high-grade proteinuria, CKD stage 3B/4/5, carotid Artery disease, or diabetes have increased risk for all-cause mortality after Renal Artery Stent placement. Patients receiving ACEI/ARBs have a decreased risk of progression to RRT, and patients receiving statins have a decreased risk of all-cause mortality.
-
Renal Artery Stent placement for restoration of Renal function in hemodialysis recipients with Renal Artery stenosis.
Journal of vascular and interventional radiology : JVIR, 2008Co-Authors: Mallik R. Thatipelli, C. Michael Johnson, James C. Andrews, Haraldur Bjarnason, Sanjay Misra, Anthony W. Stanson, Michael A. MckusickAbstract:Purpose Renal Artery Stent placement to treat Renal Artery stenosis (RAS) in patients undergoing hemodialysis is not performed commonly. We present our outcomes of discontinuation of hemodialysis after treating patients with RAS by Stent placement on acute (≤30 days of hemodialysis) and chronic hemodialysis (>30 days). Materials and Methods A retrospective study was conducted in 16 patients (nine men) with an average age of 74.6 years ± 10.6 (range, 49–86 y) who underwent treatment of 22 RAS for acute Renal failure ( n = 8) or uncontrolled hypertension with chronic hemodialysis ( n = 8). The average follow-up was 448 days ± 450 (median, 363.5 d; range, 6–1,583 d). The primary outcome consisted of discontinuation of hemodialysis, death, and transplantation. Secondary endpoints included restenosis, changes in blood pressure (and use of medications), and estimated glomerular filtration rate (eGFR). Results After the Stent procedure, eight patients were able to discontinue hemodialysis and remained free from dialysis over a mean period of 564 days ± 533. The predictors of discontinuation of hemodialysis were 24-hour proteinuria, eGFR before Renal Artery Stent placement, and size of the kidney on ultrasound studies ( P Conclusions Renal Artery Stent placement for the treatment of RAS in patients receiving hemodialysis can result in discontinuation of hemodialysis in patients with low proteinuria level and adequate kidney size and eGFR.
-
Renal Artery Stent placement: complications at a single tertiary care center.
Journal of Vascular and Interventional Radiology, 2003Co-Authors: Vladimir Ivanovic, Michael A. Mckusick, C. Michael Johnson, Enrique A. Sabater, James C. Andrews, Jerome F. Breen, Haraldur Bjarnason, Sanjay Misra, Anthony W. StansonAbstract:PURPOSE To describe complications after Renal Artery Stent placement in patients with atherosclerotic Renal Artery stenosis (RAS) at a single tertiary care center and analyze the risk factors for these complications. MATERIALS AND METHODS Medical records and angiograms of 171 patients who underwent a total of 179 consecutive percutaneous transluminal Renal Artery Stent placement (PTRS) procedures for atherosclerotic RAS were retrospectively reviewed. Data on patient comorbidities, procedure indication, lesion location, serum creatinine level, and procedure-related complications were analyzed. The Wilcoxon rank-sum test was used to assess the association of continuous risk factors with complications, and the χ 2 test was used to assess the association of categoric risk factors with outcomes. RESULTS The technical success rate for PTRS was 98%. Major complications included Renal infarction in five patients (2.8%), permanently increased serum creatinine level in 10 patients (5.6%) that required hemodialysis in five (2.8%), blood transfusion in four patients (2.2%), surgical intervention for procedure-related complications in two patients (1.1%), and deep vein thrombosis in one patient (0.6%). Overall, major complications occurred in 15 procedures (8.4%). Death within 30 days after PTRS occurred in two patients (1.1%), but neither death was definitively caused by the procedure. No risk factors were found to be significantly ( P P = .01) and have higher creatinine levels ( P = .06). CONCLUSIONS Renal Artery Stent placement allows treatment of advanced atheromatous RAS in patients with significant medical and surgical comorbidities. Complications are frequent but few have long-term significance.
-
Renal Artery Stent placement: complications at a single tertiary care center.
Journal of vascular and interventional radiology : JVIR, 2003Co-Authors: Vladimir Ivanovic, Michael A. Mckusick, C. Michael Johnson, Enrique A. Sabater, James C. Andrews, Jerome F. Breen, Haraldur Bjarnason, Sanjay Misra, Anthony W. StansonAbstract:To describe complications after Renal Artery Stent placement in patients with atherosclerotic Renal Artery stenosis (RAS) at a single tertiary care center and analyze the risk factors for these complications. Medical records and angiograms of 171 patients who underwent a total of 179 consecutive percutaneous transluminal Renal Artery Stent placement (PTRS) procedures for atherosclerotic RAS were retrospectively reviewed. Data on patient comorbidities, procedure indication, lesion location, serum creatinine level, and procedure-related complications were analyzed. The Wilcoxon rank-sum test was used to assess the association of continuous risk factors with complications, and the chi(2) test was used to assess the association of categoric risk factors with outcomes. The technical success rate for PTRS was 98%. Major complications included Renal infarction in five patients (2.8%), permanently increased serum creatinine level in 10 patients (5.6%) that required hemodialysis in five (2.8%), blood transfusion in four patients (2.2%), surgical intervention for procedure-related complications in two patients (1.1%), and deep vein thrombosis in one patient (0.6%). Overall, major complications occurred in 15 procedures (8.4%). Death within 30 days after PTRS occurred in two patients (1.1%), but neither death was definitively caused by the procedure. No risk factors were found to be significantly (P <.05) associated with major complications. Patients with Renal Artery site or Renal function complications tended to be older (P =.01) and have higher creatinine levels (P =.06). Renal Artery Stent placement allows treatment of advanced atheromatous RAS in patients with significant medical and surgical comorbidities. Complications are frequent but few have long-term significance.
Haraldur Bjarnason - One of the best experts on this subject based on the ideXlab platform.
-
treatment of in Stent restenosis in patients with Renal Artery stenosis
Journal of Vascular and Interventional Radiology, 2016Co-Authors: Edwin A Takahashi, Michael A. Mckusick, Haraldur Bjarnason, William S Harmsen, Ameet Piryani, Sanjay MisraAbstract:Abstract Purpose To determine clinical outcomes of patients treated for Renal Artery in-Stent restenosis (ISR) with atherosclerotic Renal Artery stenosis. Materials and Methods A retrospective review was performed of the clinical data of all patients who underwent Renal Artery Stent placement for atherosclerotic Renal Artery stenosis from 1996 to 2009. Medical records of patients were reviewed for relevant clinical history, including blood pressure, antihypertensive medications, and Renal function data before and after an intervention. In 1,052 patients, 1,090 Renal Artery Stent placements were performed. Of these, 101 Stents in 79 patients developed ISR, which was treated with either percutaneous transluminal angioplasty (PTA) or repeat Stent placement. Procedural details, including modality of intervention, Stent diameter, and time to restenosis, were recorded. Hypertensive agent and use of statins were recorded. Univariate analysis was performed to identify risk factors associated with restenosis after treatment of ISR. Results Patients treated with repeat Stent placement were 6.89 times more likely to lose patency after treatment than patients treated with PTA ( P Conclusions Treatment of Renal Artery ISR with PTA among patients with atherosclerotic Renal Artery stenosis has a lower rate of subsequent ISR compared with repeat Stent placement.
-
Renal Artery Stent placement for restoration of Renal function in hemodialysis recipients with Renal Artery stenosis.
Journal of vascular and interventional radiology : JVIR, 2008Co-Authors: Mallik R. Thatipelli, C. Michael Johnson, James C. Andrews, Haraldur Bjarnason, Sanjay Misra, Anthony W. Stanson, Michael A. MckusickAbstract:Purpose Renal Artery Stent placement to treat Renal Artery stenosis (RAS) in patients undergoing hemodialysis is not performed commonly. We present our outcomes of discontinuation of hemodialysis after treating patients with RAS by Stent placement on acute (≤30 days of hemodialysis) and chronic hemodialysis (>30 days). Materials and Methods A retrospective study was conducted in 16 patients (nine men) with an average age of 74.6 years ± 10.6 (range, 49–86 y) who underwent treatment of 22 RAS for acute Renal failure ( n = 8) or uncontrolled hypertension with chronic hemodialysis ( n = 8). The average follow-up was 448 days ± 450 (median, 363.5 d; range, 6–1,583 d). The primary outcome consisted of discontinuation of hemodialysis, death, and transplantation. Secondary endpoints included restenosis, changes in blood pressure (and use of medications), and estimated glomerular filtration rate (eGFR). Results After the Stent procedure, eight patients were able to discontinue hemodialysis and remained free from dialysis over a mean period of 564 days ± 533. The predictors of discontinuation of hemodialysis were 24-hour proteinuria, eGFR before Renal Artery Stent placement, and size of the kidney on ultrasound studies ( P Conclusions Renal Artery Stent placement for the treatment of RAS in patients receiving hemodialysis can result in discontinuation of hemodialysis in patients with low proteinuria level and adequate kidney size and eGFR.
-
Renal Artery Stent placement: complications at a single tertiary care center.
Journal of Vascular and Interventional Radiology, 2003Co-Authors: Vladimir Ivanovic, Michael A. Mckusick, C. Michael Johnson, Enrique A. Sabater, James C. Andrews, Jerome F. Breen, Haraldur Bjarnason, Sanjay Misra, Anthony W. StansonAbstract:PURPOSE To describe complications after Renal Artery Stent placement in patients with atherosclerotic Renal Artery stenosis (RAS) at a single tertiary care center and analyze the risk factors for these complications. MATERIALS AND METHODS Medical records and angiograms of 171 patients who underwent a total of 179 consecutive percutaneous transluminal Renal Artery Stent placement (PTRS) procedures for atherosclerotic RAS were retrospectively reviewed. Data on patient comorbidities, procedure indication, lesion location, serum creatinine level, and procedure-related complications were analyzed. The Wilcoxon rank-sum test was used to assess the association of continuous risk factors with complications, and the χ 2 test was used to assess the association of categoric risk factors with outcomes. RESULTS The technical success rate for PTRS was 98%. Major complications included Renal infarction in five patients (2.8%), permanently increased serum creatinine level in 10 patients (5.6%) that required hemodialysis in five (2.8%), blood transfusion in four patients (2.2%), surgical intervention for procedure-related complications in two patients (1.1%), and deep vein thrombosis in one patient (0.6%). Overall, major complications occurred in 15 procedures (8.4%). Death within 30 days after PTRS occurred in two patients (1.1%), but neither death was definitively caused by the procedure. No risk factors were found to be significantly ( P P = .01) and have higher creatinine levels ( P = .06). CONCLUSIONS Renal Artery Stent placement allows treatment of advanced atheromatous RAS in patients with significant medical and surgical comorbidities. Complications are frequent but few have long-term significance.
-
Renal Artery Stent placement: complications at a single tertiary care center.
Journal of vascular and interventional radiology : JVIR, 2003Co-Authors: Vladimir Ivanovic, Michael A. Mckusick, C. Michael Johnson, Enrique A. Sabater, James C. Andrews, Jerome F. Breen, Haraldur Bjarnason, Sanjay Misra, Anthony W. StansonAbstract:To describe complications after Renal Artery Stent placement in patients with atherosclerotic Renal Artery stenosis (RAS) at a single tertiary care center and analyze the risk factors for these complications. Medical records and angiograms of 171 patients who underwent a total of 179 consecutive percutaneous transluminal Renal Artery Stent placement (PTRS) procedures for atherosclerotic RAS were retrospectively reviewed. Data on patient comorbidities, procedure indication, lesion location, serum creatinine level, and procedure-related complications were analyzed. The Wilcoxon rank-sum test was used to assess the association of continuous risk factors with complications, and the chi(2) test was used to assess the association of categoric risk factors with outcomes. The technical success rate for PTRS was 98%. Major complications included Renal infarction in five patients (2.8%), permanently increased serum creatinine level in 10 patients (5.6%) that required hemodialysis in five (2.8%), blood transfusion in four patients (2.2%), surgical intervention for procedure-related complications in two patients (1.1%), and deep vein thrombosis in one patient (0.6%). Overall, major complications occurred in 15 procedures (8.4%). Death within 30 days after PTRS occurred in two patients (1.1%), but neither death was definitively caused by the procedure. No risk factors were found to be significantly (P <.05) associated with major complications. Patients with Renal Artery site or Renal function complications tended to be older (P =.01) and have higher creatinine levels (P =.06). Renal Artery Stent placement allows treatment of advanced atheromatous RAS in patients with significant medical and surgical comorbidities. Complications are frequent but few have long-term significance.
Vladimir Ivanovic - One of the best experts on this subject based on the ideXlab platform.
-
Renal Artery Stent placement: complications at a single tertiary care center.
Journal of Vascular and Interventional Radiology, 2003Co-Authors: Vladimir Ivanovic, Michael A. Mckusick, C. Michael Johnson, Enrique A. Sabater, James C. Andrews, Jerome F. Breen, Haraldur Bjarnason, Sanjay Misra, Anthony W. StansonAbstract:PURPOSE To describe complications after Renal Artery Stent placement in patients with atherosclerotic Renal Artery stenosis (RAS) at a single tertiary care center and analyze the risk factors for these complications. MATERIALS AND METHODS Medical records and angiograms of 171 patients who underwent a total of 179 consecutive percutaneous transluminal Renal Artery Stent placement (PTRS) procedures for atherosclerotic RAS were retrospectively reviewed. Data on patient comorbidities, procedure indication, lesion location, serum creatinine level, and procedure-related complications were analyzed. The Wilcoxon rank-sum test was used to assess the association of continuous risk factors with complications, and the χ 2 test was used to assess the association of categoric risk factors with outcomes. RESULTS The technical success rate for PTRS was 98%. Major complications included Renal infarction in five patients (2.8%), permanently increased serum creatinine level in 10 patients (5.6%) that required hemodialysis in five (2.8%), blood transfusion in four patients (2.2%), surgical intervention for procedure-related complications in two patients (1.1%), and deep vein thrombosis in one patient (0.6%). Overall, major complications occurred in 15 procedures (8.4%). Death within 30 days after PTRS occurred in two patients (1.1%), but neither death was definitively caused by the procedure. No risk factors were found to be significantly ( P P = .01) and have higher creatinine levels ( P = .06). CONCLUSIONS Renal Artery Stent placement allows treatment of advanced atheromatous RAS in patients with significant medical and surgical comorbidities. Complications are frequent but few have long-term significance.
-
Renal Artery Stent placement: complications at a single tertiary care center.
Journal of vascular and interventional radiology : JVIR, 2003Co-Authors: Vladimir Ivanovic, Michael A. Mckusick, C. Michael Johnson, Enrique A. Sabater, James C. Andrews, Jerome F. Breen, Haraldur Bjarnason, Sanjay Misra, Anthony W. StansonAbstract:To describe complications after Renal Artery Stent placement in patients with atherosclerotic Renal Artery stenosis (RAS) at a single tertiary care center and analyze the risk factors for these complications. Medical records and angiograms of 171 patients who underwent a total of 179 consecutive percutaneous transluminal Renal Artery Stent placement (PTRS) procedures for atherosclerotic RAS were retrospectively reviewed. Data on patient comorbidities, procedure indication, lesion location, serum creatinine level, and procedure-related complications were analyzed. The Wilcoxon rank-sum test was used to assess the association of continuous risk factors with complications, and the chi(2) test was used to assess the association of categoric risk factors with outcomes. The technical success rate for PTRS was 98%. Major complications included Renal infarction in five patients (2.8%), permanently increased serum creatinine level in 10 patients (5.6%) that required hemodialysis in five (2.8%), blood transfusion in four patients (2.2%), surgical intervention for procedure-related complications in two patients (1.1%), and deep vein thrombosis in one patient (0.6%). Overall, major complications occurred in 15 procedures (8.4%). Death within 30 days after PTRS occurred in two patients (1.1%), but neither death was definitively caused by the procedure. No risk factors were found to be significantly (P <.05) associated with major complications. Patients with Renal Artery site or Renal function complications tended to be older (P =.01) and have higher creatinine levels (P =.06). Renal Artery Stent placement allows treatment of advanced atheromatous RAS in patients with significant medical and surgical comorbidities. Complications are frequent but few have long-term significance.